Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation, January 18, 2011 - MenHibrix

Submission Type: BLA Submission ID: 125363/0 Office: OVRR

Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine

GlaxoSmithKline Biologicals

Telecon Date/Time: 18-Jan-2011 01:45 PM Initiated by FDA? Yes

Telephone Number: --b(4)------------

Communication Categorie(s):
1. Meeting Scheduling Confirmation


Telecon Summary:
Notification of VRBPAC Meeting to be held on April 6-7 2011


Non-FDA Participants: JODY ANN GOULD

Trans-BLA Group: No

Related STNs: None

Related PMCs: None

Telecon Body:

Dear Dr. Gould,

A meeting was held late last week to discuss MenHibrix. From that meeting a decision was made to take MenHibrix to VRBPAC on April 6 and 7th. The agenda topic being discussed is:

  • To discuss the use of immunologic markers for demonstration of effectiveness of meningococcal serogroups A, C, Y and W-135 conjugate vaccines administered to children less than 2 years of age.

Mr. Don Jehn is the Designated Federal Officer for VRBPAC and will be contacting you with VRBPAC/Agenda updates. He can be reached by calling:

POC: Don Jehn
Title: Designated Federal Officer for VRBPAC
Phone: 301-827-1293
Office: Division of Scientific Advisors and Consultants

Page Last Updated: 07/15/2012
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English